불면증 치료제 시장 규모, 점유율 및 성장 분석 : 치료법별, 약제 클래스별, 투여 경로별, 용도별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Insomnia Therapeutics Market size was valued at USD 6.5 Billion in 2024 and is poised to grow from USD 6.86 Billion in 2025 to USD 10.52 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The insomnia therapeutics market is primarily driven by the demand for safer and more effective sleep treatments, fueled by the increasing prevalence of chronic insomnia linked to aging populations, heightened work stress, and digital stimulation. Comprising prescription hypnotics, over-the-counter remedies, and cognitive behavioral therapy platforms, this market addresses significant issues associated with untreated insomnia, such as increased comorbidity, decreased productivity, and higher healthcare costs. Recent advancements, including regulatory approvals for innovative therapies targeting brain pathways and the integration of digital behavioral interventions, are reshaping treatment approaches. Additionally, the incorporation of AI technologies in drug development is facilitating faster target identification, enhancing molecule design, and personalizing therapies, supporting market growth and adoption among payers and clinicians while streamlining regulatory processes and encouraging R&D investments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insomnia Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insomnia Therapeutics Market Segments Analysis

Global insomnia therapeutics market is segmented by treatment type, drug class, route of administration, application, end-user, distribution channel and region. Based on treatment type, the market is segmented into Prescription Medications, Over-the-Counter (OTC) Drugs, Behavioural & Cognitive Therapies and Digital Therapeutics (CBT-I platforms). Based on drug class, the market is segmented into Benzodiazepines, Non-benzodiazepine Hypnotics, Melatonin Receptor Agonists, Orexin Receptor Antagonists, Antidepressants and Others. Based on route of administration, the market is segmented into Oral, Transdermal and Others. Based on application, the market is segmented into Chronic Insomnia, Acute Insomnia and Comorbid Insomnia. Based on end-user, the market is segmented into Hospitals, Specialty Clinics, Homecare Settings and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insomnia Therapeutics Market

The rising prevalence of chronic and acute sleep disorders has intensified the demand for effective insomnia treatments, leading healthcare providers to focus more on managing these conditions. As the number of affected individuals grows, there is a significant push for pharmaceutical companies to invest in the research, development, and commercialization of innovative therapies. Healthcare professionals and insurers are increasingly open to exploring new solutions that enhance sleep quality and daytime performance. In response, manufacturers are broadening their product pipelines and marketing initiatives to address these unmet needs, thus speeding up the introduction of new products and expanding the potential market for insomnia therapeutics.

Restraints in the Global Insomnia Therapeutics Market

The Global Insomnia Therapeutics market faces significant constraints due to complex regulatory demands that focus on long-term safety, potential for abuse, and appropriate labeling. Such stringent requirements can elongate development timelines and escalate costs for companies dedicated to insomnia treatments, often discouraging smaller developers from advancing their candidates. This cautious approach to commercialization, driven by the necessity for extensive clinical evidence and post-marketing commitments, tends to slow the introduction of innovative products. Consequently, there is a tendency to prioritize incremental advancements rather than pursuing groundbreaking therapeutic innovations, which ultimately restricts the variety of available treatment options in the market.

Market Trends of the Global Insomnia Therapeutics Market

The Global Insomnia Therapeutics market is witnessing a significant trend towards the integration of digital therapeutics, characterized by the adoption of software-based sleep interventions and mobile cognitive behavioral therapy tools. This shift is transforming traditional care models by facilitating continuous patient monitoring, enabling remote titration of treatments, and enhancing adherence support outside conventional clinical settings. Collaborations between pharmaceutical and technology firms are fostering integrated care approaches that combine behavioral modifications with pharmacological solutions, ultimately leading to improved individualized care and long-term patient outcomes. As payers and providers increasingly prioritize value-based reimbursement linked to functional recovery and quality of life, there is a growing emphasis on developing interoperable platforms that merge clinical oversight with user-friendly engagement strategies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Insomnia Therapeutics Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Prescription Medications
• Over-the-Counter (OTC) Drugs
• Behavioural & Cognitive Therapies
• Digital Therapeutics (CBT-I platforms)

Global Insomnia Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Benzodiazepines
• Non-benzodiazepine Hypnotics
• Melatonin Receptor Agonists
• Orexin Receptor Antagonists
• Antidepressants
• Others

Global Insomnia Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Transdermal
• Others

Global Insomnia Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Chronic Insomnia
• Acute Insomnia
• Comorbid Insomnia

Global Insomnia Therapeutics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Global Insomnia Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Insomnia Therapeutics Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Currax Pharmaceuticals LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurim Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purdue Pharma L.P.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pear Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations